MEK162 for Patients With RAS/RAF/MEK Activated Tumors

计划入组 110 人 · 首次发布于 2013 年 6 月 24 日

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

首次发布于 2016 年 5 月 27 日

Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.

计划入组 72 人 · 首次发布于 2019 年 12 月 6 日

RAF-709

RAF-265

C₂₄H₁₆F₆N₆O

RAS-F3

Erasca

United States

Revolution Medicines, Inc.

United States

Ikena Oncology

United States

Sysmex Inostics' RAS-RAF-SEQ Assay Gains New York Approval for Clinical Trial Use

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Servier and Black Diamond Therapeutics Forge $780M Global Licensing Deal for Novel RAF/RAS Cancer Therapy